Cavotec Group AB (STO:CCC)

Revance Therapeutics Revenue

Cavotec Group AB had revenue of 35.67M EUR in the quarter ending June 30, 2025, a decrease of -16.17%. This brings the company's revenue in the last twelve months to 163.89M, down -9.42% year-over-year. In the year 2024, Cavotec Group AB had annual revenue of 174.95M, down -3.20%.

• Revenue (ttm): 163.89M EUR
• Revenue Growth: -9.42%
• P/S Ratio: 1.00
• Revenue / Employee: 231.48K EUR
• Employees: 708
• Market Cap: 1.83B USD

Revenue Chart

* This company reports financials in EUR.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	174.95M	-5.78M	-3.20%
Dec 31, 2023	180.73M	32.89M	22.24%
Dec 31, 2022	147.85M	32.06M	27.68%
Dec 31, 2021	115.79M	452.00K	0.39%
Dec 31, 2020	115.34M	-80.68M	-41.16%